ArticleTranslational lung cancer research2025

Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.

Li-Bo Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.